ERBB2 induces an antiapoptotic expression pattern of Bcl-2 family members in node-negative breast cancer

Clinical Cancer Research

Volumn 16, Issue 2, 2010, Pages 451-460

  Petry, Ilka Brigitte ^a,c   Fieber, Esther ^a   Schmidt, Marcus ^a   Gehrmann, Mathias ^b   Gebhard, Susanne ^a   Hermes, Matthias ^c   Schormann, Wiebke ^c   Selinski, Silvia ^c   Freis, Evgenia ^c   Schwender, Holger ^c   Brulport, Marc ^c   Ickstadt, Katja ^c   Rahnenführer, Jörg ^c   Maccoux, Lindsey ^d   West, Jonathan ^d   Kölbl, Heinz ^a   Schuler, Martin ^e   Hengstler, Jan Georg ^c  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b SIEMENS AG   (Germany)

^c TU DORTMUND UNIVERSITY   (Germany)

^d LEIBNIZ INSTITUT FÜR ANALYTISCHE WISSENSCHAFTEN ISAS E V   (Germany)

^e UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROTEIN BAX; PROTEIN BCL 2; PROTEIN MCL 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BREAST CANCER; CELL STRAIN 3T3; CELL STRAIN MCF 7; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; UPREGULATION;

ANIMALS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BREAST NEOPLASMS; CARCINOMA; COHORT STUDIES; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, BCL-2; HUMANS; LYMPH NODES; MICE; MODELS, BIOLOGICAL; MULTIGENE FAMILY; NIH 3T3 CELLS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RECEPTOR, ERBB-2; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 74549213616     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-1617     Document Type: Article

References (44)

1. Schmidt M, Böhm D, von T, et al. The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res 2008;68:5405-13.
2. Hausherr CK, Schiffer IB, Gebhard S, et al. Dephosphorylation of p-ERK1/2 in relation to tumor remission after ERBB2 and Raf1 blocking therapy in a conditional mouse tumor model. Mol Carcinog 2006;45: 302-8.
3. Tanner B, Hasenclever D, Stern K, et al. ErbB-3 predicts survival in ovarian cancer. J Clin Oncol 2006;24:4317-23.
4. Micke P, Hengstler JG, Ros R, et al. C-erbB2 expression in small cell lung cancer is associated with poor prognosis. Int J Cancer 2001;92: 474-9.
5. Hengstler JG, Lange J, Kett A, et al. Contribution of c-erbB2 and topoisomerase IIα to chemoresistance in ovarian cancer. Cancer Res 1999;59:3206-14.
6. Siziopikou KP, Khan S. Correlation of HER2 gene amplification with expression of the apoptosis-suppressing genes bcl-2 and bcl-x-L in ductal carcinoma in situ of the breast. Appl Immunohistochem Mol Morphol 2005;13:14-8.
7. Milella M, Trisciuoglio D, Bruno T, et al. Trastuzumab down-regulates Bcl-2 expression and potentiates apoptosis induction by Bcl-2/Bcl-XL bispecific antisense oligonucleotides in ERBB2 gene-amplified breast cancer cells. Clin Cancer Res 2004;10:7747-56.
8. Green DR, Reed JC. Mitochondria and apoptosis. Science 1998;281: 1309-12.
9. Cory S, Adams JM. The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer 2002;2:647-56.
10. Gee JM, Robertson JF, Ellis IO, et al. Immunocytochemical localization of BCL-2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy. Int J Cancer 1994;59:619-28.
11. Leek RD, Kaklamanis L, Pezzella F, Gatter KC, Harris AL. Bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer. Br J Cancer 1994;69:135-9.
12. Henson ES, Hu X, Gibson SB. Herceptin sensitizes ErbB2-overexpressing cells to apoptosis by reducing antiapoptotic Mcl-1 expression. Clin Cancer Res 2006;12:845-53.
13. Trost TM, Lausch EU, Fees SA, et al. Premature senescence is a primary fail-safe mechanism of ERBB2-driven tumorigenesis in breast carcinoma cells. Cancer Res 2005;65:840-9.
14. Schiffer IB, Gebhard S, Heimerdinger CK, et al. Switching off ERBB2/ neu in a tetracycline controlled mouse tumor model leads to apoptosis and tumor-size dependent remission. Cancer Res 2003;63:7221-31.
15. Gossen M, Freundlieb S, Bender G, Müller G, Hillen W, Bujard H. Transcriptional activation by tetracyclines in mammalian cells. Science 1995;268:1766-9.
16. Gossen M, Bujard H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci U S A 1992;89:5547-51.
17. Baasner S, Melchner H, Klenner T, Hilgard P, Beckers T. Reversible tumorigenesis in mice by conditional expression of the HER2/ c-erbB2 receptor tyrosine kinase. Oncogene 1996;13:901-11.
18. Yamamoto S, Nagao M, Sugimori M, et al. Transcription factor expression and Notch-dependent regulation of neural progenitors in the adult rat spinal cord. J Neurosci 2001;21:9814-23.
19. Huber C, Bobek N, Kuball J, et al. Inhibitors of apoptosis confer resistance to tumour suppression by adoptively transplanted cytotoxic T-lymphocytes in vitro and in vivo. Cell Death Differ 2005;12:317-25.
20. Wesarg E, Hoffarth S, Wiewrodt R, et al. Targeting BCL-2 family proteins to overcome drug resistance in non-small cell lung cancer. Int J Cancer 2007;121:2387-94.
21. Hermes M, Schormann W, Brulport M, et al. Trastuzumab therapy vs tetracycline controlled ERBB2 downregulation: influence on tumour development in an ERBB2-dependent mouse tumour model. Br J Cancer 2008;98:1525-32.
22. Wang Y, Klijn JG, Zhang Y, et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005;365:671-9.
23. Desmedt C, Piette F, Loi S, et al. Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Can Res 2007;3:3207-14.
24. Loi S, Haibe-Kains B, Desmedt C, et al. Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol 2007;25:1239-46.
25. Spangenberg C, Lausch EU, Trost TM, et al. ERBB2-mediated transcriptional up-regulation of the α5β1 integrin fibronectin receptor promotes tumor cell survival under adverse conditions. Cancer Res 2006;66:3715-25.
26. Rizzi F, Caccamo AE, Belloni L, Bettuzzi S. Clusterin is a short half-life, poly-ubiquitinated protein, which controls the fate of prostate cancer cells. J Cell Physiol 2009;219:314-23.
27. Chi KN, Siu LL, Hirte H, et al. A phase I study of OGX-011, a 2′-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancer. Clin Cancer Res 2008;14:833-9.
28. Toffanin S, Daidone MG, Miodini P, et al. Clusterin: a potential target for improving response to antiestrogens. Int J Oncol 2008;33:791-8.
29. Shannan B, Seifert M, Boothman DA, Tilgen W, Reichrath J. Clusterin over-expression modulates proapoptotic and antiproliferative effects of 1,25(OH)2D3 in prostate cancer cells in vitro. J Steroid Biochem Mol Biol 2007;103:721-5.
30. Krüger S, Ola V, Feller AC, Fischer D, Friedrich M. Expression of cancer-testis antigen CT7 (MAGE-C1) in breast cancer: an immunohistochemical study with emphasis on prognostic utility. Pathol Oncol Res 2007;13:91-6.
31. Zhang S, Zhang D, Zhu Y, Guo H, Zhao X, Sun B. Clusterin expression and univariate analysis of overall survival in human breast cancer. Technol Cancer Res Treat 2006;5:573-8.
32. Kubasiak LA, Hernandez OM, Bishopric NH, Webster KA. Hypoxia and acidosis activate cardiac myocyte death through the Bcl-2 family protein BNIP3. Proc Natl Acad Sci U S A 2002;99:12825-30.
33. Sowter HM, Ratcliffe PJ, Watson P, Greenberg AH, Harris AL. HIF-1-dependent regulation of hypoxic induction of the cell death factors BNIP3 and NIX in human tumors. Cancer Res 2001;61:6669-73.
34. Boyd JM, Malstrom S, Subramanian T, et al. Adenovirus E1B 19 kDa and Bcl-2 proteins interact with a common set of cellular proteins. Cell 1994;79:341-51.
35. Tan EY, Campo L, Han C, et al. BNIP3 as a progression marker in primary human breast cancer; opposing functions in in situ versus invasive cancer. Clin Cancer Res 2007;13:467-74.
36. Holleman A, den Boer ML, de Menezes RX, et al. The expression of 70 apoptosis genes in relation to lineage, genetic subtype, cellular drug resistance, and outcome in childhood acute lymphoblastic leukemia. Blood 2006;107:769-76.
37. Perier C, Tieu K, Guegan C, et al. Complex I deficiency primes Bax-dependent neuronal apoptosis through mitochondrial oxidative damage. Proc Natl Acad Sci U S A 2005;102:19126-31.
38. Puthalakath H, Villunger A, O'Reilly LA, et al. Bmf: a proapoptotic BH3-only protein regulated by interaction with the myosin V actin motor complex, activated by anoikis. Science 2001;293: 1829-32.
39. Boise LH, Gonzalez-Garcia M, Postema CE, et al. Bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 1993;74:597-608.
40. Marzo I, Brenner C, Zamzami N, et al. Bax and adenine nucleotide translocator cooperate in the mitochondrial control of apoptosis. Science 1998;281:2027-31.
41. Qin W, Hu J, Guo M, et al. BNIPL-2, a novel homologue of BNIP-2, interacts with Bcl-2 and Cdc42GAP in apoptosis. Biochem Biophys Res Commun 2003;308:379-85.
42. Reimers K, Choi CY, Bucan V, Vogt PM. The Bax Inhibitor-1 (BI-1) family in apoptosis and tumorigenesis. Curr Mol Med 2008;8:148-56.
43. Götz R, Wiese S, Takayama S, et al. Bag1 is essential for differentiation and survival of hematopoietic and neuronal cells. Nat Neurosci 2005;8:1169-78.
44. Takayama S, Sato T, Krajewski S, et al. Cloning and functional analysis of BAG-1: a novel Bcl-2-binding protein with anti-cell death activity. Cell 1995;80:279-84.